[Prediction of response to lamotrigine treatment in bipolar outpatients: a multicentric, 6-month, prospective, observational study].

Q3 Pharmacology, Toxicology and Pharmaceutics
Neuropsychopharmacologia Hungarica Pub Date : 2018-06-01
Xenia Gonda, Zoltan Rihmer
{"title":"[Prediction of response to lamotrigine treatment in bipolar outpatients: a multicentric, 6-month, prospective, observational study].","authors":"Xenia Gonda,&nbsp;Zoltan Rihmer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a \"true\" unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime \"upbeat\" periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.</p>","PeriodicalId":39762,"journal":{"name":"Neuropsychopharmacologia Hungarica","volume":"20 2","pages":"40-45"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychopharmacologia Hungarica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a "true" unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime "upbeat" periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.

[预测双相情感障碍门诊患者对拉莫三嗪治疗的反应:一项多中心、6个月、前瞻性观察研究]。
在重度抑郁发作的情况下,至关重要的是要确定这是双相I或双相II障碍过程中的抑郁发作,还是“真正的”单极重度抑郁症,这可以通过筛查终生躁狂或轻躁狂发作来实现,并且可以使用轻躁狂检查表(HCL-32)来促进。在记忆中出现(轻度)躁狂的情况下,即使在抑郁症状主导临床病程的情况下,也需要进行情绪稳定治疗。然而,历史上轻度躁狂与情绪稳定拉莫三嗪治疗效果之间的关系尚未被研究过。在我们目前的研究中,我们旨在分析hcc -32的临床和社会心理特征,确定终生“乐观”期,并确定基线评估的hcc -32第三部分总分与6个月拉莫三嗪治疗期间的缓解和复发率之间是否存在关联。我们的研究结果表明,基线HCL-32组第三部分评分与第4次就诊时的缓解率呈中等强相关性,第5次就诊时可观察到强烈的显著相关性。总体复发率与基线HCL-32第三部分评分有显著的强相关性。因此,我们的研究结果表明,基线评估的终生轻躁评分与6个月拉莫三嗪治疗期间较高的缓解率和较低的复发率之间存在关联,这表明拉莫三嗪对病程中的轻躁患者有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuropsychopharmacologia Hungarica
Neuropsychopharmacologia Hungarica Medicine-Medicine (all)
CiteScore
1.60
自引率
0.00%
发文量
8
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信